Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.34 |
| ▸ | USP2 | O75604 | 5/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323571 | 0.84 | HRH3 (0.42) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23324887 | 0.74 | HRH3 (0.43) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL20148750 | 0.73 | CYP2D6 (0.46) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23323569 | 0.72 | CYP3A4 (0.44) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL10111444 | 0.70 | CYP2D6 (0.39) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23323568 | 0.70 | HRH3 (0.39) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL25884737 | 0.70 | HRH3 (0.36) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23323567 | 0.69 | CYP2D6 (0.39) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL23325421 | 0.69 | HRH3 (0.39) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL10128467 | 0.68 | USP2 (0.49) | HRH3CYP2D6CYP1A2CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HRH3 3890/4885CYP2D6 4714/4885CYP1A2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.